Omada Health Reports Second Quarter 2026 Results and Announces CEO Transition

Omada Health posts strong Q2 growth and profitability, but forward drivers lack quantifiable detail.

What the company is saying

Omada Health emphasizes a sharp turnaround in financial performance, highlighting 43% year-over-year revenue growth to $88 million and a swing from a $5 million net loss to a $5 million net profit in Q2 2026. The company frames its narrative around operational scale, citing a 45% increase in total members and record gross margins of 73%. Forward guidance is presented with confidence, projecting full-year revenue of $334–$340 million and adjusted EBITDA of $21–$27 million, both up from prior ranges. Leadership transition is positioned as a planned evolution, with Sean Duffy moving to Executive Chair and Wei-Li Shao named incoming CEO, effective January 1, 2027. The announcement spotlights partnerships and new product launches, such as the HCSC expansion and cholesterol management offering, but does not provide financial specifics for these initiatives. The tone is upbeat and data-driven for realised results, while forward-looking statements are aspirational but lack supporting detail.

What the data suggests

The disclosed numbers confirm a strong financial trajectory: revenue rose from $61 million in Q2 2025 to $88 million in Q2 2026, a 44% increase. Gross margin improved from 66% to 73%, and non-GAAP gross margin from 68% to 74%. Net income moved from a $5 million loss to a $5 million profit, and adjusted EBITDA improved from a $0.2 million loss to $11 million positive. Total members grew 45% year over year, with trailing twelve-month revenue per member up 2% to $284. Cash reserves are robust at $222 million, and the balance sheet shows $252.7 million in equity against $75.5 million in liabilities. Guidance for 2026 implies 30% revenue growth and a fourfold increase in adjusted EBITDA over 2025. No realised financial impact is disclosed for new partnerships or product launches, and forward-looking claims about future revenue streams remain unquantified.

Analysis

The announcement's tone is positive but proportionate to the strong, realised financial results disclosed. Key metrics—revenue, gross margin, net income, and adjusted EBITDA—are all reported with clear year-over-year improvement, including a swing to profitability. While several forward-looking statements are present (leadership transition, new partnerships, product launches, and future events), these are typical for quarterly updates and do not dominate the narrative. No large capital outlay or long-dated, uncertain returns are disclosed; the only forward-looking revenue from a new program is explicitly stated as arriving in 2027, but this is not presented as a near-term driver. The language is factual, and all major financial claims are supported by numerical evidence. There is no evidence of narrative inflation or overstatement relative to the disclosed results.

Risk flags

• ●Forward-looking operational claims, such as the HCSC partnership and cholesterol management launch, lack supporting financial data or quantified impact. This raises uncertainty about their contribution to future growth and whether they can materially affect results.
• ●The leadership transition, with Sean Duffy moving to Executive Chair and Wei-Li Shao becoming CEO, introduces execution risk. While planned transitions can be smooth, changes at the top level may disrupt strategy or culture, especially if not accompanied by clear succession planning evidence.
• ●Revenue guidance for 2026 is ambitious, targeting 30% growth and a fourfold increase in adjusted EBITDA. If member growth or per-member revenue slows, or if new initiatives underperform, the company may miss these targets.
• ●No information is provided on customer concentration, competitive threats, or regulatory risks, leaving potential blind spots in the risk profile. The absence of these disclosures limits a full assessment of downside scenarios.

Bottom line

Omada Health delivers a convincing set of Q2 results, with strong revenue growth, margin expansion, and a return to profitability. The financial disclosures are detailed and credible for realised performance, but operational claims about partnerships and new products are not backed by quantifiable evidence. Leadership transition adds a layer of uncertainty, though the company presents it as orderly. The 2026 guidance is aggressive but plausible if current trends continue, yet the lack of detail on forward drivers means these should be treated as potential rather than guaranteed upside. For investors, the core business is performing well, but new growth levers remain unproven. The most important takeaway is that realised financial momentum is strong, but future catalysts require more evidence before being factored into valuation.

Announcement summary

(NASDAQ:OMDA) Omada Health, Inc. reported revenue of $88 million for the second quarter ended June 30, 2026, compared with total revenue of $61 million in Q2 2025. Gross margin reached 73% in the second quarter, up from 66% in Q2 2025, and non-GAAP gross margin was 74%, up from 68% in Q2 2025. Net income for the second quarter was $5 million, compared with a net loss of $5 million in Q2 2025, and adjusted EBITDA was $11 million, compared with an adjusted EBITDA loss of $0.2 million in Q2 2025. Total Members increased 45% year over year, and trailing twelve-month revenue per total member grew approximately 2% year over year to $284. Cash and cash equivalents were $222 million as of June 30, 2026. The company projects revenue in the range of $334 million to $340 million and adjusted EBITDA in the range of $21 million to $27 million for the year ending December 31, 2026, with the midpoint representing 30% revenue growth and a fourfold increase in adjusted EBITDA compared with 2025. Omada Health also announced that Sean Duffy will transition to Founder and Executive Chair and Wei-Li Shao will become CEO effective January 1, 2027.

Disagree with this article?